<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Reduced-intensity-conditioning (RIC) hematopoietic stem cell transplantation (HSCT) is markedly underutilized in the elderly, in part because the impact of advanced age on outcomes is poorly understood </plain></SENT>
<SENT sid="1" pm="."><plain>We retrospectively analyzed outcomes in 158 consecutive <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancy</z:e> patients aged &gt; or =60 years (median, 63 years; range: 60-71 years) undergoing fludarabine/<z:chebi fb="0" ids="28901">busulfan</z:chebi>-based RIC, with a median-follow-up of 34 months (range: 12.0-85.7) </plain></SENT>
<SENT sid="2" pm="."><plain>Multivariate analysis was undertaken for factors having an impact on outcome </plain></SENT>
<SENT sid="3" pm="."><plain>For the patients aged &gt; or =60 years, 2-year nonrelapse mortality (NRM) and relapse was 10% and 54.6%, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Two-year overall and progression-free survival (OS, PFS) was 46% and 35%, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Grade II-IV <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (aGVHD, cGVHD) incidence was 19.6% and 45.9%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Comparing 110 patients aged 60-64 years versus 48 patients aged &gt; or =65 years, 2-year NRM and relapse was 10.5% versus 8.3% (P = .84) and 53.5% versus 56.3% (P = .31), respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Grade II-IV aGVHD and cGVHD incidence was 19.1% versus 22.9% (P = .52) and 51.8% versus 32.5% (P = .01), respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Two-year OS and PFS was 49% versus 41% (P = .11) and 36% versus 35% (P = .24), respectively </plain></SENT>
<SENT sid="9" pm="."><plain>In a multivariate Cox-model, high-risk disease associated with poorer PFS (hazard ratio [HR] = 2.1, P = .01) and OS (HR = 1.84, P = .03); <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo>/<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> diagnosis (HR = 1.66, P = .03) and matched-related donor (HR = 1.62, P = .03) associated with poorer PFS </plain></SENT>
<SENT sid="10" pm="."><plain>RIC HSCT is well tolerated, with reasonable survival in elderly patients </plain></SENT>
<SENT sid="11" pm="."><plain>Age is not associated with impaired outcomes </plain></SENT>
<SENT sid="12" pm="."><plain>HSCT should not be excluded solely based on advanced patient age </plain></SENT>
</text></document>